Horizon Pays $1.1 Billion for Hyperion’s Rare Disease Drugs

March 30, 2015 | Big buyout for an orphan drug company. Hyperion's two therapies treat urea cycle disorder, and earned the company $113.6 million in 2014. Xconomy